Twenty laboratories across the world participated in the study organized by the Consortium for Top-Down Proteomics. Three mAbs were provided for intact / subunit mass analysis or Top-Down / Middle-Down sequence confirmation: NIST mAb, SiLuLite and Trastuzumab.
Direct fragmentation of the intact NISTmAb Light Chain confirms 89 % of the sequence in a single spectrum.
Essential for the acceptance of intact mass, MU and MD approaches is a streamlined software environment that provides a fair degree of automation to reduce hands-on analysis time during biopharmaceutical characterization in the Biotech industry and CROs. In our view, this condition is met with the technologies and software that we employed to this study´s tasks. Crucial for automation is the high ruggedness of monoisotopic peak assignment and the high sequence
coverage provided by the technologies we used, together with the software designed for routine biopharmaceutical characterization. BioPharma Compass reduces the analysis time drastically and renders MU/MD analysis a new and complementary approach to tryptic digests for the biotech industry, which reduces analysis time at increased confidence and reduced costs.
For Research Use Only. Not for use in clinical diagnostic procedures.